| In millions, except per share items | Jun-30-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Interest income: |
| Interest income on loans | | 48.5 | 45.7 | 46.1 | 46.7 | 47.9 | 48.4 | 48.7 |
| Interest income on investments | | 5.5 | 5.2 | 4.9 | 4.5 | 4.2 | 4.0 | 3.7 |
| Interest income on repurchase agreements | | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| | | 54.9 | 51.5 | 51.3 | 51.5 | 52.3 | 52.5 | 52.6 |
| Interest expense: |
| Interest on deposits | | 4.0 | 3.0 | 3.1 | 3.4 | 3.9 | 4.8 | 6.0 |
| | | 4.7 | 3.4 | 3.4 | 3.7 | 4.2 | 5.0 | 6.2 |
| Net interest income | | 50.2 | 48.1 | 47.9 | 47.7 | 48.1 | 47.5 | 46.3 |
| Provision for loan losses | | | | | | 0.7 | | 7.0 |
| Net interest income after provision for loan losses | | 50.2 | 48.3 | 48.1 | 47.7 | 47.4 | 44.5 | 39.3 |
| Other non-interest income | | 6.7 | 5.9 | 6.2 | 6.4 | 7.2 | 7.3 | 7.3 |
| Total non-interest income | | 6.7 | 5.9 | 6.2 | 6.4 | 7.2 | 7.3 | 7.3 |
| Non-interest expenses | | 38.0 | 33.6 | 32.6 | 31.9 | 32.0 | 31.9 | 31.1 |
| Pre-tax income before non-recurring items | | 20.3 | 20.8 | 21.9 | 22.2 | 22.7 | 19.8 | 15.6 |
| Non-recurring items | | 1.4 | | | | | | |
| Asset impairment | | | | 0.2 | | | | |
| Pre-tax income | | 18.9 | 20.6 | 21.7 | 22.2 | 22.7 | 19.8 | 15.6 |
| Income taxes | | 3.2 | 3.6 | 3.8 | 3.9 | 4.1 | 3.5 | 2.6 |
| Tax rate | | 17.0% | 17.5% | 17.3% | 17.7% | 17.9% | 17.7% | 16.9% |
| Net income | | 15.7 | 17.0 | 18.0 | 18.3 | 18.6 | 16.3 | 12.9 |
| Net margin | | 27.5% | 31.4% | 33.1% | 33.8% | 34.1% | 31.5% | 27.7% |
| |
| Basic EPS | | $2.66 | $2.87 | $2.99 | $2.99 | $2.98 | $2.59 | $2.04 |
| Diluted EPS | | $2.66 | $2.86 | $2.98 | $2.98 | $2.97 | $2.58 | $2.03 |
| |
| Shares outstanding (basic) | | 5.9 | 5.9 | 6.0 | 6.1 | 6.2 | 6.3 | 6.4 |
| Shares outstanding (diluted) | | 5.9 | 5.9 | 6.0 | 6.1 | 6.3 | 6.3 | 6.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |